NCT04670757View on ClinicalTrials.gov

Safety and Pharmacokinetics of JAK/ROCK Inhibitor in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

65

Participants

Timeline

Start Date

December 8, 2020

Primary Completion Date

September 8, 2021

Study Completion Date

September 8, 2021

Conditions

Healthy

Interventions

DRUG

CPL409116

IMP administration, tablets contain CPL409116 as an active ingredient

DRUG

Placebo

Placebo comparator

Trial Locations (1)

05-830

BioResearch Group Sp. z o.o., Kajetany

Sponsors

Lead Sponsor

Celon Pharma SA

All Listed Sponsors

collaborator

National Center for Research and Development, Poland

OTHER

lead

Celon Pharma SA

INDUSTRY